Skip to content
Screener

Pfizer PFE Royalty — Revenue

Other product segments

Eliquis
$2.43B+21.1%
Vyndaqel family
$1.76B+9.1%
Prevnar Family
$1.69B+1.8%
Ibrance
$1.06B+0.9%
All Other Hospital and Biosimilars
$952M—
All other Primary Care
$699M-5.0%
Padcev
$667M+23.1%
All other Specialty Care
$566M+45.1%
Xtandi
$534M-5.7%
Nurtec ODT/Vydura
$421M+17.3%
All other Oncology
$376M-0.3%
Oncology Biosimilars
$359M+1.7%
Lorbrena
$354M+41.0%
Pfizer CentreOne
$289M+5.9%
Xeljanz
$251M-22.0%
Comirnaty
$232M-58.9%
Braftovi/Mektovi
$223M+22.5%
Inlyta
$218M-10.3%
Abrysvo
$208M+45.5%
Zavicefta (Outside the U.S. and Canada)
$199M+22.1%
Adcetris
$196M-23.1%
Inflectra
$171M—
Orgovyx
$146M—
Enbrel (Outside the U.S. and Canada)
$142M-7.8%
Octagam
$138M—
Tukysa
$138M+4.5%
Sulperazon (Outside the U.S. and Canada)
$116M-30.1%
Bosulif
$113M-24.2%
Zithromax
$112M-29.1%
Cibinqo
$94M+36.2%
Genotropin
$94M-11.3%
Elrexfio
$89M+4.7%
FSME-IMMUN/TicoVac
$81M—
Talzenna
$57M+23.9%
Tivdak
$34M-26.1%
Paxlovid
$21M—

Similar metrics at other companies

Lantheus Holdings logo
LNTHLicenseand Royalty Revenues — Revenue
$11.25M+222%
TEC
TECHRoyalty — Revenue
$4.97M-1.4%
Abercrombie & Fitch logo
ANFRoyalty — Revenue
$15.75M+2.9%
Axsome Therapeutics logo
AXSMRoyalty — Revenue
$4.07M+269%
Opko Health logo
OPKRoyalty — Revenue
$6.4M+4.9%
PTC Therapeutics logo
PTCTRoyalty — Revenue
$46.84M+28.5%

Other financials

Income statement

See full
Revenue$15.0B+2.6%
Gross profit$10.9B+0.6%
Net income-$248.0M-109%
EPS (diluted)-$0.04-108%

Balance sheet

See full
Cash & equivalents$1.8B+18.8%
Total debt$64.4B+4.9%
Total equity$90.1B-0.3%
Total assets$207.62B-0.2%

Cash flow

See full
Operating cash flow$2.6B+12.0%
CapEx$436.0M-22.7%
Free cash flow$2.2B+23.0%

Valuation

See full
Market cap$147.11B+8.1%
Enterprise value$209.77B+9.2%
P/E16.6×—
P/S2.3×+0.2×

Profitability

See full
Gross margin73.2%+1.1pp
Net margin15.7%—
FCF margin18%+8.8pp

Returns & leverage

See full
Return on equity10.6%—
Debt / equity0.7×0.0×
Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Pfizer’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 7:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000078003-26-000054
(MILLIONS, EXCEPT PER SHARE DATA)Three Months Ended / March 29,2026Three Months Ended / March 30,2025
Revenues:
Product revenues$11,715$11,294
Alliance revenues2,3392,113
Royalty revenues396308
Total revenues14,45113,715
Costs and expenses:
Cost of sales(a)3,5482,845
Selling, informational and administrative expenses(a)2,9613,031

Item 1.

FAQ

What is Pfizer's royalty — revenue?
Pfizer (PFE) reported royalty — revenue of $396M in Q1 2026.
How has Pfizer's royalty — revenue changed year-over-year?
Pfizer's royalty — revenue increased by 28.6% year-over-year, from $308M to $396M.
What is the long-term trend for Pfizer's royalty — revenue?
Over 3 years (2022 to 2025), Pfizer's royalty — revenue has grown at a 25.0% compound annual growth rate (CAGR), from $845M to $1.65B.
What does royalty — revenue mean?
This metric represents the income generated from licensing intellectual property, patents, or proprietary technologies to third-party entities. It reflects the monetization of the company's research and development pipeline without the direct costs associated with manufacturing or commercializing the end products. This revenue stream is typically high-margin and serves as a strategic indicator of the company's ability to extract value from its broader innovation portfolio.

Ask your AI about Pfizer's royalty — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude